IN8bio, Inc. (INAB) Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by IN8bio, Inc. on October 27, 2025. The report addresses Item 8.01 (Other Events) regarding the presentation of new preclinical data for the Company's gamma-delta T cell engager (g d -TCE) program, INB-619, at the 2025 American College of Rheumatology (ACR) Convergence Meeting in Chicago.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than financial performance.
Material Changes
The material change reported is the dissemination of new preclinical data for the INB-619 program. No financial or operational changes relative to a prior comparable period are detailed in this document.
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the data presentation. The full details of the preclinical data are contained in the press release attached as Exhibit 99.1. The filing does not explicitly list new risks, contingencies, or unusual items beyond the standard disclosure of the event.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific details on the INB-619 preclinical data presented at the ACR Convergence Meeting.
- Verify the clinical development timeline for INB-619 following the presentation of this data.
- Check subsequent filings for any updates on the Company's cash position or capital requirements, as this 8-K does not contain financial statements.